{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:49:42Z","timestamp":1793321382607,"version":"4.5.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"\n Background<\/jats:title>\n This study aimed to evaluate the aflibercept biosimilars compared to the reference product aflibercept (Eylea\u00ae) in terms of efficacy, safety, and immunogenicity in patients with neovascular age-related macular degeneration (nAMD).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We searched PubMed, Web of Science, Cochrane Library, and Embase from inception to 13 August 2025. We included studies reporting changes in best-corrected visual acuity (BCVA), changes in central subfield thickness (CST), changes in the leakage lesion of choroidal neovascularization (CNV), and adverse events from baseline to endpoint. All statistical analyses were performed using Stata 18.0 software and assessed the certainty of evidence for each outcome using the GRADE approach.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of seven studies involving 2,829 participants were included. There were no statistically significant differences in visual and anatomical outcomes between the aflibercept biosimilars (SB15, P041, SDZ-AFL, AVT06, SCD411, ABP 938, and QL1207) and the reference aflibercept. No significant differences were detected between aflibercept biosimilars and the reference aflibercept with respect to serious ocular and non-ocular adverse events [relative risk (RR) = 1.71, 95% confidence interval (CI): 0.70, 4.19;\n I<\/jats:italic>\n \n 2<\/jats:italic>\n <\/jats:sup>\n = 0.0%,\n P<\/jats:italic>\n = 0.913; RR = 1.08, 95% CI: 0.82, 1.42;\n I<\/jats:italic>\n \n 2<\/jats:italic>\n <\/jats:sup>\n = 0.0%,\n P<\/jats:italic>\n = 0.936, respectively). Although a slightly higher rate of treatment-emergent adverse events (TEAEs) was noted in the biosimilar group (RR = 1.07, 95% CI: 1.00\u20131.15; I\n 2<\/jats:sup>\n = 26.1%), the difference was not statistically significant (\n P<\/jats:italic>\n = 0.248).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Based on the seven included randomized controlled clinical trials, aflibercept biosimilars demonstrated comparable safety and efficacy to the reference aflibercept. Future research requires more rigorous studies.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fphar.2026.1719493","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T07:15:44Z","timestamp":1771312544000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of aflibercept biosimilars compared to aflibercept in the treatment of neovascular age-related macular degeneration: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yating","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Kunshan Hospital of Traditional Chinese Medicine","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyue","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai University Affiliated Heping Eye Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixun","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease,Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Affiliated Xinhua Hospital of Dalian University, Dalian","place":["Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/14712598.2025.2519531","article-title":"A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degeneration","volume":"25","author":"Agostini","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.2147\/OPTH.S524395","article-title":"Efficacy and safety of aflibercept biosimilars relative to reference aflibercept therapy for neovascular age-related macular degeneration: a systematic review and meta-analysis","volume":"19","author":"Aljuhani","year":"2025","journal-title":"Clin. Ophthalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.18553\/jmcp.2021.27.9.1260","article-title":"Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis","volume":"27","author":"Almony","year":"2021","journal-title":"J. Manag. Care & Specialty Pharm."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1097\/IAE.0000000000004174","article-title":"Efficacy and safety of the proposed biosimilar aflibercept, sdz-afl, in patients with neovascular age-related macular degeneration: 52-week results from the phase 3 mylight study","volume":"44","author":"Bordon","year":"2024","journal-title":"Retina"},{"key":"B6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/archophthalmol.2011.140","article-title":"Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-hispanic white population in the United States with age-related macular degeneration","volume":"129","author":"Bressler","year":"2011","journal-title":"Archives Ophthalmol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2244670","DOI":"10.1001\/jamanetworkopen.2022.44670","article-title":"Comparison of uptake and prices of biosimilars in the US, Germany, and Switzerland","volume":"5","author":"Carl","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"B8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","article-title":"Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy","volume":"9","author":"Deng","year":"2022","journal-title":"Genes & Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.survophthal.2006.10.017","article-title":"Ocular neovascularization: basic mechanisms and therapeutic advances","volume":"52","author":"Dorrell","year":"2007","journal-title":"Surv. Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40259-019-00395-w","article-title":"Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price","volume":"34","author":"Dutta","year":"2020","journal-title":"BioDrugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical classification of age-related macular degeneration","volume":"120","author":"Ferris","year":"2013","journal-title":"Ophthalmology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1159\/000517520","article-title":"Age-related macular degeneration: pathophysiology, management, and future perspectives","volume":"244","author":"Flores","year":"2021","journal-title":"Ophthalmologica."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2025.07.015","article-title":"Randomized trial of biosimilar ABP 938 compared with reference aflibercept in adults with neovascular age-related macular degeneration","author":"Friedman","year":"2025","journal-title":"Ophthalmol. Retina"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1175","DOI":"10.1016\/S2214-109X(25)00143-3","article-title":"Global burden of vision impairment due to age-related macular degeneration, 1990-2021, with forecasts to 2050: a systematic analysis for the global burden of disease study 2021","volume":"13","year":"2025","journal-title":"Lancet Glob. Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B18","first-page":"105","article-title":"Vascular endothelial growth factors and their inhibitors in ocular neovascular disorders","volume":"4","author":"Homayouni","year":"2009","journal-title":"J. Ophthalmic Vis. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"14752","DOI":"10.1038\/s41598-024-65815-6","article-title":"Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration","volume":"14","author":"Kang","year":"2024","journal-title":"Sci. Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.oret.2024.02.012","article-title":"Evaluating the efficacy and safety of aflibercept biosimilar (P041) compared with originator product in patients with neovascular age-related macular degeneration","volume":"8","author":"Karkhaneh","year":"2024","journal-title":"Ophthalmol. Retina"},{"key":"B21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ophtha.2006.10.040","article-title":"Fifteen-year cumulative incidence of age-related macular degeneration: the beaver dam eye study","volume":"114","author":"Klein","year":"2007","journal-title":"Ophthalmology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"8567912","DOI":"10.1155\/2018\/8567912","article-title":"Current evidence for the prevention of endophthalmitis in Anti-VEGF intravitreal injections","volume":"2018","author":"Lau","year":"2018","journal-title":"J. Ophthalmol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40123-023-00836-4","article-title":"Efficacy and safety of biosimilar QL1207 vs. the reference aflibercept for patients with neovascular age-related macular degeneration: a randomized phase 3 trial","volume":"13","author":"Li","year":"2024","journal-title":"Ophthalmol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"100852","DOI":"10.1016\/j.eclinm.2021.100852","article-title":"Global economic productivity losses from vision impairment and blindness","volume":"35","author":"Marques","year":"2021","journal-title":"eClinicalMedicine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"101354","DOI":"10.1016\/j.eclinm.2022.101354","article-title":"The economics of vision impairment and its leading causes: a systematic review","volume":"46","author":"Marques","year":"2022","journal-title":"eClinicalMedicine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.37765\/ajmc.2022.88809","article-title":"Projected US savings from biosimilars, 2021-2025","volume":"28","author":"Mulcahy","year":"2022","journal-title":"Am. J. Manag. Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/sj.eye.6702547","article-title":"Comparison of visual acuity outcomes in predominantly classic vs occult lesions in age-related macular degeneration treated with photodynamic therapy","volume":"22","author":"Potter","year":"2008","journal-title":"Eye (Lond)."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e001561","DOI":"10.1136\/bmjophth-2023-001561","article-title":"Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial","volume":"8","author":"Sadda","year":"2023","journal-title":"BMJ Open Ophthalmol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"B32","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.mcna.2021.01.003","article-title":"Age-related and macular degeneration","volume":"105","author":"Thomas","year":"2021","journal-title":"Med. Clin. N. Am."},{"key":"B33","unstructured":"Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product\n \n \n 2015"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1719493\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:30:09Z","timestamp":1771932609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1719493\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":33,"alternative-id":["10.3389\/fphar.2026.1719493"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1719493","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"article-number":"1719493"}}